{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:25:28Z","timestamp":1770359128245,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005134.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000}}],"reference-count":157,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005134.pub3","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T15:22:31Z","timestamp":1477927351000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pentasaccharides for the prevention of venous thromboembolism"],"prefix":"10.1002","volume":"2016","author":[{"given":"Kezhou","family":"Dong","sequence":"first","affiliation":[{"name":"The 2nd Jiangsu Province Hospital of TCM, Nanjing University of Chinese Medicine; Department of Respiration; No.155, Hanzhong Road Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[{"name":"Shanghai Daopei Hospital, Fudan University; Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[{"name":"BenQ Medical Center, Nanjing Medical University; Department of Radiotherapy; Nanjing Jiangsu Province China 210019"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[{"name":"National Institute on Aging, NIH; Laboratory of Epidemiology and Population Science; 7201 Wisconsin Ave, Suite 3C-309 Bethesda Maryland USA MD 20814"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Gao","sequence":"additional","affiliation":[{"name":"Shanghai Daopei Hospital, Fudan University; Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daopei","family":"Lu","sequence":"additional","affiliation":[{"name":"Shanghai Daopei Hospital, Fudan University; Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Zhu","sequence":"additional","affiliation":[{"name":"The 2nd Jiangsu Province Hospital of TCM, Nanjing University of Chinese Medicine; Department of Respiration; No.155, Hanzhong Road Nanjing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"10.1002\/14651858.CD005134.pub3-BIB0001|cit1","unstructured":"Anon A multicentre dose finding study of once daily injection of natural pentasaccharide for the prevention of deep vein thrombosis after total hip replacement GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1067\/mhj.2001.117032","article-title":"Pentasaccharide (org31540\/sr90107a) clinical trials update: lessons for practice","volume":"142","author":"Turpie","year":"2001","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0003|cit3","unstructured":"Anon Safety study of fondaparinux sodium to prevent venous thromboembolic events (APOLLO). A multicenter, randomized, double-blind, parallel group trial to demonstrate the efficacy of fondaparinux sodium in association with intermittent pneumatic compression versus intermittent pneumatic compression used alone for the prevention of venous thromboembolic events in subjects at increased risk undergoing major abdominal surgery GlaxoSmithKline Clinical Trial Register 2011"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0004|cit4","unstructured":"Del Priore G Herzog TJ Bauer KA Caprini JA Comp P Gent M Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of venous thromboembolism after major abdominal surgery: results of the APOLLO study Gynecologic Oncology 2006 S21"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0005|cit5","first-page":"Abstract number","article-title":"Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of VTE after major abdominal surgery: results of the APOLLO study","volume":"3","author":"Turpie","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9","key":"10.1002\/14651858.CD005134.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/j.1538-7836.2007.02657.x","article-title":"Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison","volume":"5","author":"Turpie","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"Abstract 279","DOI":"10.1182\/blood.V106.11.279.279","article-title":"Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of venous thromboembolism after major abdominal surgery: the randomized APOLLO study","volume":"106","author":"Turpie","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0008|cit8","unstructured":"Anon Clinical evaluation of GSK576428 (fondaparinux sodium) in prevention of venous thromboembolism (VTE) after abdominal surgery GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"7","key":"10.1002\/14651858.CD005134.pub3-BIB0009|cit9","first-page":"679","article-title":"Clinical evaluation of fondaparinux for prevention of venous thromboembolism after abdominal surgery. A randomized open-label study of fondaparinux and intermittent pneumatic compression as a benchmark","volume":"24","author":"Sakon","year":"2008","journal-title":"Rinsho Iyaku - Journal of Clinical Therapeutics & Medicines"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0010|cit10","unstructured":"Anon A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS) GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005134.pub3-BIB0015|cit11","first-page":"105","article-title":"Thromboprophylaxis with fondaparinux in acutely ill medical patients aged 75 years or more","volume":"5","author":"Cohen","year":"2004","journal-title":"The Hematology Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005134.pub3-BIB0016|cit12","first-page":"54","article-title":"Thromboprophylaxis with fondaparinux in acutely ill medical patients with moderate renal impairment","volume":"5","author":"Cohen","year":"2004","journal-title":"The Hematology Journal"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0013|cit13","first-page":"15a-Abstract 42","article-title":"Fondaparinux for the prevention of VTE in acutely ill medical patients","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"7537","key":"10.1002\/14651858.CD005134.pub3-BIB0011|cit14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0012|cit15","first-page":"Abstract number","article-title":"Thromboprophylaxis with fondaparinux in acutely Ill medical patients aged 75 years or more, or with moderate renal impairment","volume":"3","author":"Cohen","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl 1 July","key":"10.1002\/14651858.CD005134.pub3-BIB0014|cit16","first-page":"Abstract P2046","article-title":"Fondaparinux vs. placebo for the prevention of venous thromboembolism in patients (artemis)","volume":"1","author":"Cohen","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0017|cit17","unstructured":"Wilmott R Cohen AT Benefit of fondaparinux in medical patients: a subgroup analysis 16th European Chapter Congress of the International Union of Angiology, 2005 Oct; Glasgow, UK"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0018|cit18","unstructured":"Wilmott R Cohen AT Thromboprophylaxis with fondaparinux in acutely ill medical patients aged 75 years or more, or with moderate renal impairment 16th European Chapter Congress of the International Union of Angiology, 2005 Oct; Glasgow, UK"},{"issue":"32","key":"10.1002\/14651858.CD005134.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12959-015-0062-0","article-title":"Low dose compared to variable dose warfarin and to fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study","volume":"13","author":"Bern","year":"2015","journal-title":"Thrombosis Journal"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0020|cit20","unstructured":"Anonymous Evaluation of fondaparinux (also called ARIXTRA) 2.5 mg subcutaneously once daily for the treatment of superficial thrombophlebitis (also known as superficial vein thrombosis) GlaxoSmithKline Clinical Trial Register 2013"},{"issue":"13","key":"10.1002\/14651858.CD005134.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux for the treatment of superficial-vein thrombosis in the legs","volume":"363","author":"Decousus","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2013-04-498014","article-title":"Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study","volume":"122","author":"Leizorovicz","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00402-013-1691-z","article-title":"Is routine chemoprophylaxis necessary for prevention of venous thromboembolism following knee arthroplasty in a low incidence population?","volume":"133","author":"Cho","year":"2013","journal-title":"Archives of Orthopaedic and Trauma Surgery"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0024|cit24","unstructured":"Anon A multicenter, randomized, double-blind, placebo controlled, parallel group, dose response study of subcutaneous (Org31540\/SR90107A) in the prevention of venous thromboembolism after elective total hip replacement surgery GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00264-007-0360-7","article-title":"Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients","volume":"32","author":"Fuji","year":"2008","journal-title":"International Orthopaedics"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0026|cit26","unstructured":"Anonymous A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose response study of subcutaneous (Org31540\/SR90107A) in the prevention of venous thromboembolism after elective total knee replacement surgery GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00264-007-0360-7","article-title":"Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients","volume":"32","author":"Fuji","year":"2008","journal-title":"International Orthopaedics"},{"issue":"3","key":"10.1002\/14651858.CD005134.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.soard.2014.10.003","article-title":"The EFFORT trial. Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial","volume":"11","author":"Steele","year":"2015","journal-title":"Surgery for Obesity and Related Diseases"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0029|cit29","unstructured":"Anon European Pentasaccharide Hip Elective Surgery Study (EPHESUS). A multicenter, randomized, double-blind comparison of once daily subcutaneous (Org31540\/SR90107A) with enoxaparin for the prevention of deep vein thrombosis or symptomatic pulmonary embolism in patients undergoing elective hip replacement surgery GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"9345","key":"10.1002\/14651858.CD005134.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(02)11542-X","article-title":"Fondaparinux versus enoxaparin for prevention of venous thromboembolism","volume":"360","author":"Borja","year":"2002","journal-title":"Lancet"},{"issue":"9319","key":"10.1002\/14651858.CD005134.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen MR. Bauer","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0032|cit32","unstructured":"Anon FONDAparinux in patients with a plaster CAST (FONDACAST) GlaxoSmithKline Clinical Trial Register 2011"},{"issue":"10","key":"10.1002\/14651858.CD005134.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/jth.12395","article-title":"Comparison of fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury","volume":"11","author":"Samama","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD005134.pub3-BIB0034|cit34","first-page":"153","article-title":"Comparison of fondaparinux with low-molecular-weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury","volume":"4","author":"Samama","year":"2014","journal-title":"Annales Francaises de Medecine d'Urgence"},{"issue":"Suppl S3","key":"10.1002\/14651858.CD005134.pub3-BIB0035|cit35","first-page":"5","article-title":"Prevention of venous thromboembolism after an isolated, non-surgical below-knee injury. Benefit\/risk of fondaparinux vs. low molecular weight heparin: the Fondacast study","volume":"11","author":"Samama","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0036|cit36","first-page":"88","article-title":"Subgroup analysis of the FONDACAST study comparing fondaparinux to low-molecular-weight heparin for the prevention of venous thromboembolism after an isolated, non-surgical below-knee injury","volume":"11 (Suppl S2)","author":"Samama","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12959-014-0034-9","article-title":"A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery","volume":"13","author":"Fuji","year":"2015","journal-title":"Thrombosis Journal"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2015.10.013","article-title":"A randomized study of the safety and efficacy of fondaparinux versus placebo in the prevention of venous thromboembolism after coronary artery bypass graft surgery","volume":"171","author":"Kolluri","year":"2016","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0039|cit39","unstructured":"Anon Arixtra VTE Prevention Study - Fondaparinux compared with enoxaparin in the prevention of venous thromboembolism (VTE) in Chinese patients undergoing elective knee replacement, hip surgery or a revision of components GlaxoSmithKline Clinical Trial Register 2008"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0040|cit40","unstructured":"Anon Fondaparinux compared with enoxaparin in the prevention of venous thromboembolism in Taiwanese patients undergoing elective knee replacement GlaxoSmithKline Clinical Trial Register 2008"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cjtee.2015.04.003","article-title":"Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection","volume":"18","author":"Li","year":"2015","journal-title":"Chinese Journal of Traumatology"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0042|cit42","unstructured":"Agnelli G Bergqvist D Cohen A Gallus A Gent M A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus study Journal of Thrombosis and Haemostasis 2003 Abstract OC006"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD005134.pub3-BIB0043|cit43","first-page":"Abstract 40","article-title":"A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS study","volume":"102","author":"Agnelli","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD005134.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"British Journal of Surgery"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0045|cit45","unstructured":"Anon A multicenter, multinational, randomized, double-blind study to compare the efficacy and safety of fondaparinux sodium (Org31540\/SR90107A) with dalteparin (Fragmin) in the prevention of venous thromboembolic events in high-risk abdominal surgery (PEGASUS) GlaxoSmithKline Clinical Trial Register 2005"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0046|cit46","unstructured":"Anon A multicenter, multinational, randomized, double-blind comparison of subcutaneous (Org31540\/SR90107A) with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective major knee surgery or a revision (PENTAMAKS) GlaxoSmithKline Clinical Trial Register 2008"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0047|cit47","first-page":"490a","article-title":"The PENTAMAKS Study. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective major knee surgery","volume":"96","author":"Bauer","year":"2000","journal-title":"Blood"},{"issue":"18","key":"10.1002\/14651858.CD005134.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD005134.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood-2005-05-1938","article-title":"Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin","volume":"106","author":"Warkentin","year":"2005","journal-title":"Blood"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0051|cit50","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1067\/mhj.2001.117032","article-title":"Pentasaccharide (Org31540\/SR90107A) clinical trials update: lessons for practice","volume":"142","author":"Turpie","year":"2001","journal-title":"American Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD005134.pub3-BIB0050|cit51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD005134.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood-2005-05-1938","article-title":"Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin","volume":"106","author":"Warkentin","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0053|cit53","unstructured":"Anon A multicenter, multinational, randomized, double-blind comparison of subcutaneous (Org31540\/SR90107A) with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective hip replacement or a revision. PENTATHLON 2000 GlaxoSmithKline Clinical Trial 2008"},{"issue":"491A","key":"10.1002\/14651858.CD005134.pub3-BIB0055|cit54","first-page":"Abstract A2112","article-title":"The PENTATHALON 2000 Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism","volume":"96","author":"Turpie","year":"2000","journal-title":"Blood"},{"issue":"9319","key":"10.1002\/14651858.CD005134.pub3-BIB0054|cit55","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0056|cit56","unstructured":"Anon A multicenter, multinational, randomized double-blind comparison study of subcutaneous (Org31540\/SR90107A) versus enoxaparin 40 mg o.d. in the prevention of deep vein thrombosis and symptomatic pulmonary embolism in hip fracture surgery (PENTHIFRA) GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"490A","key":"10.1002\/14651858.CD005134.pub3-BIB0057|cit57","first-page":"Abstract 2110","article-title":"The PENTHIFRA Study. Comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) after hip fracture surgery","volume":"96","author":"Eriksson","year":"2000","journal-title":"Blood"},{"issue":"18","key":"10.1002\/14651858.CD005134.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0059|cit59","unstructured":"Anon A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540\/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery (PENTIHFRA PLUS) GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0060|cit60","first-page":"P2050","article-title":"No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study","volume":"1","author":"Bauer","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"22 Suppl 7","key":"10.1002\/14651858.CD005134.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/ajhp\/60.suppl_7.S15","article-title":"Novel concepts: emerging data and the role of extended prophylaxis following hip fracture surgery","volume":"60","author":"Dobesh","year":"2003","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0065|cit62","unstructured":"Eriksson BI A multicenter, randomized, placebo-controlled, double-blind study of fondaparinux for the prolonged prevention of venous thromboembolism in hip fracture surgery Abstracts of the Sicot\/Sirot XXII World Congress 2002 318"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"Abstract P2064","DOI":"10.1111\/j.1538-7836.2003.tb05548.x","article-title":"Consistency of efficacy of extended thromboprophylaxis with fondaparinux (Arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA-PLUS study","volume":"1","author":"Eriksson","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7 Suppl 2","key":"10.1002\/14651858.CD005134.pub3-BIB0062|cit64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.arth.2004.06.012","article-title":"Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients","volume":"19","author":"Eriksson","year":"2004","journal-title":"Journal of Arthroplasty"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0064|cit65","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","article-title":"Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study","volume":"163","author":"Eriksson","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0066|cit66","first-page":"Abstract number","article-title":"Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra) a new synthetic and selective inhibitor of factor Xa in the PENTHIFRA-PLUS study","volume":"1","author":"Lassen","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0067|cit67","first-page":"Abstract P2062","article-title":"Efficacy of fondaparinux (Arixtra) in extended thromboprophylaxis in hip fracture surgery is irrespective of patient and surgical characteristics: subgroup analyses of the Penthifra-Plus study","volume":"1","author":"Lassen","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"3_Meeting Abstr","key":"10.1002\/14651858.CD005134.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"535D","DOI":"10.1378\/chest.1921851","article-title":"Fondaparinux versus low molecular weight heparin following esophagectomy: results from a randomized and controlled trial","volume":"145","author":"Shen","year":"2014","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD005134.pub3-BIB0069|cit69","first-page":"251","article-title":"Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population?","volume":"93","author":"Yokote","year":"2011","journal-title":"Journal of Bone and Joint Surgery British Volume"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0070|cit70","unstructured":"Anon A multicentre pilot study of natural pentasaccharide (SR90107A \/Org31540) for the prevention of deep venous thrombosis after total hip replacement GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"9609","key":"10.1002\/14651858.CD005134.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0072|cit72","unstructured":"Anon Clinical evaluation of GSK576428 (fondaparinux sodium) in the treatment of acute pulmonary thromboembolism (PE) GlaxoSmithKline Clinical Trial Register 2009"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0073|cit73","unstructured":"Anon Clinical evaluation of GSK576428 (fondaparinux sodium) in prevention of venous thromboembolism after elective total hip replacement surgery GlaxoSmithKline Clinical Trial Register 2008"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0074|cit74","unstructured":"Anon Clinical evaluation of GSK576428 (fondaparinux sodium) in prevention of venous thromboembolism after hip fracture surgery GlaxoSmithKline Clinical Trial Register 2008"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"49\u201353","DOI":"10.1016\/j.curtheres.2013.02.003","article-title":"Fondapar\u0131nux versus nadroparin for prevention of venous thromboembolism after elective hip and knee arthroplasty","volume":"74","author":"Argun","year":"2013","journal-title":"Current Therapeutic Research"},{"issue":"2","key":"10.1002\/14651858.CD005134.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.knee.2005.08.010","article-title":"Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin","volume":"13","author":"Bonneux","year":"2006","journal-title":"Knee"},{"issue":"6","key":"10.1002\/14651858.CD005134.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jth.12546","article-title":"Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study","volume":"12","author":"Buller","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9811","key":"10.1002\/14651858.CD005134.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(11)61505-5","article-title":"Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial","volume":"379","author":"B\u00fcller","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0079|cit79","first-page":"73","article-title":"Graduated compression stockings do not add to the efficacy of fondaparinux for thromboprophylaxis in hip replacement surgery. A multi-centre, multi-national, randomised, open-label study","volume":"91-B","author":"Cohen","year":"2009","journal-title":"Journal of Bone and Joint Surgery British Volume"},{"issue":"7","key":"10.1002\/14651858.CD005134.pub3-BIB0080|cit80","first-page":"887","article-title":"The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study","volume":"89","author":"Cohen","year":"2007","journal-title":"Journal of Bone and Joint Surgery British Volume"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2010.04100.x","article-title":"Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis","volume":"9","author":"The EQUINOX","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0083|cit83","unstructured":"Anon Flexibility in administration of Arixtra for prevention of symptomatic venous thromboembolism in orthopedic surgery GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arth.2005.05.023","article-title":"Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery","volume":"21","author":"Colwell","year":"2006","journal-title":"Journal of Arthroplasty"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0085|cit85","first-page":"Abstract OR061","article-title":"FLEXTRA: early vs delayed initiation of postoperative fondaparinux prophylaxis after joint replacement: a clinical outcome study","volume":"3","author":"Davidson","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD005134.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"216\u201322","DOI":"10.3109\/s10165-011-0496-6","article-title":"Postoperative prophylactic effect of fondaparinux for prevention of deep venous thrombosis after cemented total hip replacement:a comparative study","volume":"22","author":"Kawaji","year":"2012","journal-title":"Modern Rheumatology \/ The Japan Rheumatism Association"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0087|cit87","first-page":"1037","article-title":"The clinical efficacy and safety of fondaparinux combined with tirofiban hydrochloride in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention","volume":"52","author":"Li","year":"2013","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"18","key":"10.1002\/14651858.CD005134.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"The Matisse Investigators","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0090|cit90","unstructured":"NCT00521885 Comparison of arixtra vs. lovenox to prevent blood clots in medically ill patients (BRiEF) ClinicalTrials.gov 2007"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0091|cit91","unstructured":"NCT00539942 Study of arixtra to prevent blood clots in women undergoing abdominopelvic surgery\u00a0for likely gynecologic malignancy ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0092|cit92","unstructured":"Anon A multicenter, concurrent control, randomized, open-label, assessor-blind, dose-ranging study (of Org 31540\/SR90107A) in the prophylaxis of deep vein thrombosis in subjects undergoing total knee replacement surgery (PENTATAK) GlaxoSmithKline Clinical Trial Register 2008"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation","volume":"2","author":"PERSIST Investigators","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/01.CIR.102.22.2726","article-title":"Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A\/ Org31540) with pure anti-factor Xa activity. A phase II evaluation","volume":"102","author":"The Rembrandt Investigators","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.acvd.2014.09.009","article-title":"Safety of fondaparinux in transoesophageal echocardiography-guided electric cardioversion of atrial fibrillation (SAFE-AF) study: a pilot study","volume":"108","author":"Cohen","year":"2014","journal-title":"Archives of Cardiovascular Diseases"},{"issue":"5","key":"10.1002\/14651858.CD005134.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00776-009-1365-4","article-title":"Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery","volume":"14","author":"Sasaki","year":"2009","journal-title":"Journal of Orthopaedic Science"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00776-010-0011-5","article-title":"Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery","volume":"16","author":"Sasaki","year":"2011","journal-title":"Journal of Orthopaedic Science"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2004-05-2010","article-title":"Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin","volume":"105","author":"Savi","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0099|cit99","first-page":"2477","article-title":"The efficacy of fondaparinux for the prophylaxis of venous thromboembolism after resection for colorectal cancer","volume":"59","author":"Tsutsumi","year":"2012","journal-title":"Hepatogastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"van Gogh Investigators","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"A54","DOI":"10.1136\/heartjnl-2013-303992.165","article-title":"Efficacy and safety of fondaparinux during thrombolytic therapy in acute ST elevation myocardial infarction patients","volume":"99","author":"Xin","year":"2013","journal-title":"Heart"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0103|cit103","unstructured":"Yamaoka YI Nishikawa T The impact of fondaparinux on the prophylaxis of venous thromboembolism: the efficacy, safety and prognosis after resection for colorectal cancer Annals of Surgical Oncology 2014"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0104|cit104","first-page":"138","article-title":"Efficacy and safety of fondaparinux during thrombolytic therapy in acute ST elevation myocardial infarction patients","volume":"126","author":"Zhao","year":"2013","journal-title":"Cardiology (Switzerland)"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jcpt.12315","article-title":"Fondaparinux vs. enoxaparin in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) treated with percutaneous coronary intervention and tirofiban: an exploratory study in China","volume":"40","author":"Zhao","year":"2015","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0106|cit106","unstructured":"EUCTR2007-003746-15-DE Prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation WHO International Clinical Trials Registry 2008"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0107|cit107","unstructured":"Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux - Fondaparinux and heart failure WHO International Clinical Trials Registry"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0108|cit108","unstructured":"JPRN-UMIN000002444 Randomized study of anti-coagulant therapy to prevent postoperative deep venous thrombosis\/pulmonary embolism WHO International Clinical Trials Registry 2009"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0109|cit109","unstructured":"JPRN-UMIN000007005 The efficacy and safety of anticoagulant therapy Arixtra Injection for the prevention of the vein thromboembolism in laparoscopic colorectal surgery WHO International Clinical Trials Registry 2011"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0110|cit110","unstructured":"Phase III study of efficacy of fondaparinux on the prevention of post-operative venous thromboembolism in patients undergoing with laparoscopic colorectal cancer surgery WHO International Clinical Trials Registry"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0111|cit111","unstructured":"NCT00881088 Prophylaxis of thromboembolic complications trial: thromboprophylaxis needed in below knee plaster cast immobilization for ankle and foot fractures (PROTECT) ClinicalTrials.gov 2009"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/j.1538-7836.2012.04908.x","article-title":"Safety and efficacy of low dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study","volume":"10","author":"Ageno","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"V49","DOI":"10.1016\/S0049-3848(99)00207-8","article-title":"Prevention of venous thromboembolism","volume":"97","author":"Agnelli","year":"2000","journal-title":"Thrombosis Research"},{"issue":"2","key":"10.1002\/14651858.CD005134.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00001721-199703000-00005","article-title":"Absence of cross-reactivity of SR90107A\/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia","volume":"8","author":"Amiral","year":"1997","journal-title":"Blood Coagulation and Fibrinolysis"},{"issue":"7454","key":"10.1002\/14651858.CD005134.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"British Medical Journal"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"364s","DOI":"10.1378\/chest.124.6_suppl.364S","article-title":"New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology","volume":"124","author":"Bauer","year":"2003","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005134.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.0960-135X.2005.01454.x","article-title":"Fondaparinux: an update on new study results","volume":"35","author":"Bauersachs","year":"2005","journal-title":"European Journal of Clinical Investigation"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2147\/vhrm.2006.2.4.365","article-title":"Review\u00a0of\u00a0fondaparinux\u00a0sodium injection for the prevention of venous thromboembolism in patients undergoing surgery","volume":"2","author":"Bergqvist","year":"2006","journal-title":"Vascular Health and Risk Management"},{"issue":"9319","key":"10.1002\/14651858.CD005134.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(02)08660-9","article-title":"Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention","volume":"359","author":"Bounameaux","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0120|cit120","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007038.pub2","article-title":"Factor Xa inhibitors for acute coronary syndromes","author":"Brito","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005134.pub3-BIB0121|cit121","first-page":"252","article-title":"Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice","volume":"104","author":"Delavenne","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD005134.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00228-012-1263-0","article-title":"Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery","volume":"68","author":"Delavenne","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD005134.pub3-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001100.pub3","article-title":"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism","author":"Erkens","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ejvs.2002.1778","article-title":"Incidence of diagnosed deep vein thrombosis in the general population: systematic review","volume":"25","author":"Fowkes","year":"2003","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","article-title":"Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Geerts","year":"2004","journal-title":"Chest"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0128|cit128","first-page":"381S\u2013453S","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practive Guidelines (8th Edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0129|cit129","unstructured":"Brozek J Oxman A Sch\u00fcnemann H. [Computer program on www.gradepro.org] GRADEpro 2014"},{"issue":"6","key":"10.1002\/14651858.CD005134.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"Hansson","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.4065\/76.11.1102","article-title":"Incidence of venous thromboembolism in hospitalised patients vs community residents","volume":"76","author":"Heit","year":"2001","journal-title":"Mayo Clinic Proceedings"},{"issue":"11","key":"10.1002\/14651858.CD005134.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"Abstract 910","DOI":"10.1182\/blood.V106.11.910.910","article-title":"Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US","volume":"106","author":"Heit","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0133|cit133","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0134|cit134","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"196\u2013204","DOI":"10.1111\/j.1756-5391.2009.01023.x","article-title":"Balancing treatment allocations by clinician or center in randomized trials allows unacceptable levels of treatment prediction","volume":"2","author":"Hills","year":"2009","journal-title":"Journal of Evidence-based Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1365-2796.2003.01226.x","article-title":"Short- and long-acting synthetic pentasaccharides","volume":"254","author":"Koopman","year":"2003","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005134.pub3-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4140\/TCP.n.2015.329","article-title":"New oral anticoagulants: clinical parameters and uses in practice","volume":"30","author":"Metzger","year":"2015","journal-title":"Consultant Pharmacist"},{"issue":"6","key":"10.1002\/14651858.CD005134.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1160\/TH11-09-0640","article-title":"Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study","volume":"107","author":"Mismetti","year":"2012","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/01.mcp.0000136901.80029.37","article-title":"Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review","volume":"10","author":"Nijkeuter","year":"2004","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"18","key":"10.1002\/14651858.CD005134.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1016\/S0021-9258(18)42309-5","article-title":"Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement","volume":"267","author":"Olson","year":"1992","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1538-7836.2011.04564.x","article-title":"Isolated distal deep vein thrombosis: what we know and what we are doing","volume":"10","author":"Palareti","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0142|cit142","unstructured":"Paty I Trellu M Paquet N Sibille M Perez Y Ortiz J Neutralization by avidin of anticoagulant activity of biotinylated idraparinux, the first and unique reversible long-acting anticoagulant Journal of Thrombosis and Haemostasis 2007 O T-050"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2010.03746.x","article-title":"Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion","volume":"8","author":"Paty","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"20","key":"10.1002\/14651858.CD005134.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.103.20.2453","article-title":"Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis","volume":"103","author":"Pinede","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD005134.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/13543784.17.5.773","article-title":"Idraparinux:\u00a0review\u00a0of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders","volume":"17","author":"Prandoni","year":"2008","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005981.pub2","article-title":"Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement","author":"Salazar","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD005134.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1538-7836.2008.03089.x","article-title":"Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy","volume":"6","author":"Savi","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/14397595.2014.997424","article-title":"Prophylactic effect of fondaparinux and enoxaparin for preventing pulmonary embolism after total hip or knee arthroplasty: a retrospective observational study using the Japanese Diagnosis Procedure Combination database","volume":"25","author":"Shoda","year":"2015","journal-title":"Modern Rheumatology \/ The Japan Rheumatism Association"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and post marketing reports of bleeding","volume":"368","author":"Southworth","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005134.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0959-8049(96)00477-7","article-title":"Pretargeting strategies for radio-immuno guided tumour localisation and therapy","volume":"33","author":"Stoldt","year":"1997","journal-title":"European Journal of Cancer"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD005134.pub3-BIB0151|cit151","first-page":"371S","article-title":"New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies","volume":"124","author":"Turpie","year":"2003","journal-title":"Chest"},{"issue":"22 Suppl 7","key":"10.1002\/14651858.CD005134.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/ajhp\/60.suppl_7.S20","article-title":"Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders","volume":"60","author":"Turpie","year":"2003","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1002\/14651858.CD005134.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"397\u2013402","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events: meta-analysis of non inferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005134.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1538-7836.2009.03298.x","article-title":"The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials","volume":"7","author":"Veyrat-Follet","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD005134.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomised trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005134.pub3-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005134","article-title":"Pentasaccharides for the prevention of venous thromboembolism","author":"Nichol","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD005134.pub3-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005134.pub2","article-title":"Pentasaccharides for the prevention of venous thromboembolism","author":"Song","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005134.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T02:09:38Z","timestamp":1718071778000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005134.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":157,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005134.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]}}}